NCT02586493 - Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects | Biotech Hunter

Enrollment

278

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

March 1, 2016

Study Completion Date

March 15, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Placebo

Subjects will receive 1 inhalation once-daily until visit 2.

OTHER

Questionnaire

ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.

Trial Locations (16)

23225

GSK Investigational Site, Richmond

29303

GSK Investigational Site, Spartanburg

29379

GSK Investigational Site, Union

29464

GSK Investigational Site, Mt. Pleasant

29615

GSK Investigational Site, Greenville

29640

GSK Investigational Site, Easley

29678

GSK Investigational Site, Seneca

29732

GSK Investigational Site, Rock Hill

32174

GSK Investigational Site, Ormond Beach

32825

GSK Investigational Site, Orlando

33765

GSK Investigational Site, Clearwater

35501

GSK Investigational Site, Jasper

45231

GSK Investigational Site, Cincinnati

55402

GSK Investigational Site, Minneapolis

55441

GSK Investigational Site, Plymouth

29406-7108

GSK Investigational Site, Charleston